Heart medication for women with chest pain and small vessel disease
Part of Heart & circulation, Pain clinical trials.
This trial tests a diabetes medication called SGLT2 inhibitors to see if it can improve blood flow to the heart and reduce chest pain in women who have small vessel heart disease (microvascular dysfunction) but not blocked large arteries. Participants will take the medication and be monitored for symptom relief and heart function improvements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman aged 18 or older
- Have had chest pain or other symptoms suggesting reduced blood flow to the heart, leading to a heart catheterization or CT scan within the past 2 years
- Have no major blockages in the large heart arteries (less than 50% narrowing)
- Have confirmed small vessel heart disease, called coronary microvascular dysfunction (CMD), measured by a special heart MRI test
- Never have taken an SGLT2 inhibitor medication before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking an inorganic nitrate supplement can improve chest pain and blood flow in women who have chest pain but no blocked heart arteries. It may help if your heart's small blood vessels are not working properly.
This study tests whether a daily pill called dapagliflozin can reduce chest pain and improve blood flow in people who have chest pain but no major blockages in their heart arteries. It may help if your heart's small blood vessels are not working properly.
This trial tests whether a small pressure-reducing device placed in a heart vein (the coronary sinus) can reduce symptoms in people with ongoing chest pain from tiny blood vessel problems. It is for angina that has not improved despite standard heart medicines, and only if special heart tests show reversible reduced blood flow.
This early-phase study tests whether dapagliflozin can improve tiny blood-vessel function in women who have heart-ache-like symptoms but no major blockage on heart scans. If it works, it may help symptoms related to “microvascular” heart circulation problems.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
Hear when a new Angina Patients With Non-obstructive Coronary Artery Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.